


Reality Check



Dishman Pharma gets a boost

The stock of contract research and manufacturing company Dishman Pharma hit a new high last week. It has doubled in the last three months, primarily on two counts: First, strong performance in the June quarter came as a positive surprise. The company reported revenue growth of 10 per cent for the quarter, compared with the same period last year. Its consolidated net profit zoomed 59 per cent year-on-year to ₹38 crore, helped by a strong improvement in operating performance.

Second, Dishman last week announced that it had signed an agreement with the US drug major Janssen Pharmaceuticals to supply the active pharmaceutical ingredient (API) for the latter's tuberculosis drug brand Sirturo. Dishman recently commenced supplies of the drug API and will cater to Janssen's global requirement. This should add to Dishman's revenue and profit over the next few quarters.

NALINAKANTHI V

Company